Product portfolio

Donor Screening - Nucleic Acid Testing (NAT)

Over 60 million blood and plasma donations were tested on Roche NAT systems each day.

From launching the first Nucleic Acid Testing assays for blood screening, Roche has consistently remained in the forefront in keeping the blood supply safe through active surveillance of emerging infections and through rapid development of screening solutions.

Roche NAT instruments, assays and reagents have been developed using the gold standard real-time Polymerase Chain Reaction (PCR) technology, a very sensitive and high-performing technology that detects DNA and RNA molecules of infectious agents such as HIV/HCV/HBV at an early stage of an infection. Easily integrated into pre- and post-analytic solutions they enable donor screening facilities to automate operations, boost throughput and achieve quicker turnaround times - leading to greater overall workflow efficiency.

Roche’s state-of-the-art NAT assays provide comprehensive genotype coverage and excellent sensitivity.  Together with analyzers that provide efficient workflows, they deliver fast results. Roche’s leading molecular diagnostic solutions deliver predictable operational outcomes for laboratories and help reduce the risk of disease transmission and adverse health effects in patients. 


View all products

Designed to work together

cobas 6800

cobas® 6800 System

Transform your testing experience for IVD applications—just 2 simple user interactions per run and up to 8 hours of walk-away time.

cobas 8800

cobas® 8800 System

Unparalleled performance with minimal operator interaction revolutionizes the future of high-throughput applications. 


*Products of the Roche Blood Safety Solutions portfolio are not commercially available in all regions. Please contact your local Roche representative regarding availability.


  1. Data on file. Roche Diagnostics, Inc.
Found 0 results in